Announcement • Jun 30
Sinotherapeutics Inc. to Report First Half, 2026 Results on Aug 28, 2026 Sinotherapeutics Inc. announced that they will report first half, 2026 results on Aug 28, 2026 Reported Earnings • Apr 30
Full year 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.28 in FY 2024) Full year 2025 results: EPS: CN¥0.11 (down from CN¥0.28 in FY 2024). Revenue: CN¥446.6m (down 13% from FY 2024). Net income: CN¥47.5m (down 63% from FY 2024). Profit margin: 11% (down from 25% in FY 2024). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Apr 30
Sinotherapeutics Inc., Annual General Meeting, May 28, 2026 Sinotherapeutics Inc., Annual General Meeting, May 28, 2026, at 09:30 China Standard Time. Location: No. 99, Haike Road, Pudong New Area, Shanghai China Announcement • Mar 30
Sinotherapeutics Inc. to Report Q1, 2026 Results on Apr 30, 2026 Sinotherapeutics Inc. announced that they will report Q1, 2026 results on Apr 30, 2026 New Risk • Mar 05
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (11% net profit margin). Reported Earnings • Mar 05
Full year 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.28 in FY 2024) Full year 2025 results: EPS: CN¥0.11 (down from CN¥0.28 in FY 2024). Revenue: CN¥446.5m (down 13% from FY 2024). Net income: CN¥48.9m (down 62% from FY 2024). Profit margin: 11% (down from 25% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Announcement • Dec 26
Sinotherapeutics Inc. to Report Fiscal Year 2025 Results on Apr 30, 2026 Sinotherapeutics Inc. announced that they will report fiscal year 2025 results on Apr 30, 2026 Announcement • Sep 30
Sinotherapeutics Inc. to Report Q3, 2025 Results on Oct 31, 2025 Sinotherapeutics Inc. announced that they will report Q3, 2025 results on Oct 31, 2025 Reported Earnings • Aug 24
Second quarter 2025 earnings released: EPS: CN¥0.05 (vs CN¥0.07 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.05 (down from CN¥0.07 in 2Q 2024). Revenue: CN¥110.7m (up 3.8% from 2Q 2024). Net income: CN¥25.1m (down 20% from 2Q 2024). Profit margin: 23% (down from 29% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat. Announcement • Jun 30
Sinotherapeutics Inc. to Report First Half, 2025 Results on Aug 23, 2025 Sinotherapeutics Inc. announced that they will report first half, 2025 results on Aug 23, 2025 New Risk • May 07
New major risk - Revenue and earnings growth Earnings have declined by 7.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • May 05
Sinotherapeutics Inc., Annual General Meeting, May 29, 2025 Sinotherapeutics Inc., Annual General Meeting, May 29, 2025, at 09:30 China Standard Time. Location: No. 99, Haike Road, Pudong New Area, Shanghai China Reported Earnings • Apr 30
Full year 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.13 in FY 2023) Full year 2024 results: EPS: CN¥0.28 (up from CN¥0.13 in FY 2023). Revenue: CN¥511.6m (up 71% from FY 2023). Net income: CN¥127.7m (up 109% from FY 2023). Profit margin: 25% (up from 20% in FY 2023). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥9.36, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total returns to shareholders of 5.8% over the past year. New Risk • Apr 07
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 458% Dividend yield: 0.6% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Mar 28
Sinotherapeutics Inc. to Report Q1, 2025 Results on Apr 30, 2025 Sinotherapeutics Inc. announced that they will report Q1, 2025 results on Apr 30, 2025 Reported Earnings • Feb 27
Full year 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.13 in FY 2023) Full year 2024 results: EPS: CN¥0.28 (up from CN¥0.13 in FY 2023). Revenue: CN¥512.7m (up 71% from FY 2023). Net income: CN¥128.2m (up 110% from FY 2023). Profit margin: 25% (up from 20% in FY 2023). The increase in margin was driven by higher revenue. Announcement • Dec 27
Sinotherapeutics Inc. to Report Fiscal Year 2024 Results on Apr 30, 2025 Sinotherapeutics Inc. announced that they will report fiscal year 2024 results on Apr 30, 2025 Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥12.68, the stock trades at a trailing P/E ratio of 52x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total returns to shareholders of 9.6% over the past year. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥11.41, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 3.1% over the past year. New Risk • Oct 30
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. New Risk • Oct 09
New minor risk - Dividend sustainability The company has a short dividend paying track record. Continuous dividend paying years: 1 Dividend yield: 0.5% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Profit margins are more than 30% lower than last year (23% net profit margin). Announcement • Sep 30
Sinotherapeutics Inc. to Report Q3, 2024 Results on Oct 30, 2024 Sinotherapeutics Inc. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥9.75, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year. Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.029 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.029 in 2Q 2023). Revenue: CN¥106.6m (up 56% from 2Q 2023). Net income: CN¥31.3m (up 108% from 2Q 2023). Profit margin: 29% (up from 22% in 2Q 2023). The increase in margin was driven by higher revenue. Announcement • Jun 28
Sinotherapeutics Inc. to Report First Half, 2024 Results on Aug 31, 2024 Sinotherapeutics Inc. announced that they will report first half, 2024 results on Aug 31, 2024 Announcement • May 01
Sinotherapeutics Inc., Annual General Meeting, May 31, 2024 Sinotherapeutics Inc., Annual General Meeting, May 31, 2024, at 14:00 China Standard Time. Location: No. 99, Haike Road, Pudong New Area, Shanghai China Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.02 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.05 (up from CN¥0.02 in 1Q 2023). Revenue: CN¥111.4m (up 163% from 1Q 2023). Net income: CN¥22.9m (up 197% from 1Q 2023). Profit margin: 21% (up from 18% in 1Q 2023). The increase in margin was driven by higher revenue. New Risk • Apr 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (11% average weekly change). Profit margins are more than 30% lower than last year (20% net profit margin). Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥7.27, the stock trades at a trailing P/E ratio of 54.4x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 54% over the past year. Announcement • Mar 29
Sinotherapeutics Inc. to Report Q1, 2024 Results on Apr 30, 2024 Sinotherapeutics Inc. announced that they will report Q1, 2024 results on Apr 30, 2024 Reported Earnings • Feb 25
Full year 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.22 in FY 2022) Full year 2023 results: EPS: CN¥0.13 (down from CN¥0.22 in FY 2022). Revenue: CN¥298.8m (up 21% from FY 2022). Net income: CN¥60.5m (down 35% from FY 2022). Profit margin: 20% (down from 38% in FY 2022). The decrease in margin was driven by higher expenses. Announcement • Feb 23
Sinotherapeutics Inc. (SHSE:688247) announces an Equity Buyback for CNY 70 million worth of its shares. Sinotherapeutics Inc. (SHSE:688247) announces a share repurchase program. Under the program, the company will repurchase up to its A shares for a total of CNY 70 million. The shares will be purchased at a price not exceeding CNY 13.53 per share. The repurchased shares will be used for the implementation of ESOP or equity incentive plan. The program will be valid for 12 months. New Risk • Feb 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (33% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.0% average weekly change). Profit margins are more than 30% lower than last year (26% net profit margin). Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥8.37, the stock trades at a trailing P/E ratio of 54.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 51% over the past year. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.052 (vs CN¥0.059 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.052 (down from CN¥0.059 in 3Q 2022). Revenue: CN¥102.6m (up 74% from 3Q 2022). Net income: CN¥21.3m (down 21% from 3Q 2022). Profit margin: 21% (down from 46% in 3Q 2022). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.029 (vs CN¥0.05 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.029 (down from CN¥0.05 in 2Q 2022). Revenue: CN¥68.3m (up 5.7% from 2Q 2022). Net income: CN¥15.1m (down 25% from 2Q 2022). Profit margin: 22% (down from 31% in 2Q 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥14.15, the stock trades at a trailing P/E ratio of 79.8x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Announcement • Jun 28
Sinotherapeutics Inc. to Report First Half, 2023 Results on Aug 30, 2023 Sinotherapeutics Inc. announced that they will report first half, 2023 results on Aug 30, 2023 Valuation Update With 7 Day Price Move • May 05
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥13.25, the stock trades at a trailing P/E ratio of 74.7x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Reported Earnings • Mar 01
Full year 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.33 in FY 2021) Full year 2022 results: EPS: CN¥0.22 (down from CN¥0.33 in FY 2021). Revenue: CN¥247.6m (down 22% from FY 2021). Net income: CN¥92.9m (down 31% from FY 2021). Profit margin: 38% (down from 43% in FY 2021). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥18.03, the stock trades at a trailing P/E ratio of 58x. Average trailing P/E is 38x in the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment deteriorated over the past week After last week's 24% share price decline to CN¥19.32, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Dec 07
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥13.86, the stock trades at a trailing P/E ratio of 44.6x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.12 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.059 (down from CN¥0.12 in 3Q 2021). Revenue: CN¥59.1m (down 26% from 3Q 2021). Net income: CN¥26.9m (down 45% from 3Q 2021). Profit margin: 46% (down from 62% in 3Q 2021). Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥11.71, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in China.